Literature DB >> 33577641

Establishing Pediatric Mouse Models of the Hematopoietic Acute Radiation Syndrome and the Delayed Effects of Acute Radiation Exposure.

Andrea M Patterson1, Rajendran Sellamuthu1, P Artur Plett1, Carol H Sampson1, Hui Lin Chua1, Alexa Fisher1, Sasidhar Vemula1, Hailin Feng1, Barry P Katz2, Gregory Tudor3, Steven J Miller4, Thomas J MacVittie5, Catherine Booth3, Christie M Orschell1.   

Abstract

Medical countermeasures (MCMs) for hematopoietic acute radiation syndrome (H-ARS) should be evaluated in well-characterized animal models, with consideration of at-risk populations such as pediatrics. We have developed pediatric mouse models of H-ARS and delayed effects of acute radiation exposure (DEARE) for efficacy testing of MCMs against radiation. Male and female C57BL/6J mice aged 3, 4, 5, 6, 7 and 8 weeks old (±1 day) were characterized for baseline hematopoietic and gastrointestinal parameters, radiation response, efficacy of a known MCM, and DEARE at six and 12 months after total-body irradiation (TBI). Weanlings (age 3 weeks) were the most radiosensitive age group with an estimated LD50/30 of 712 cGy, while mice aged 4 to 8 weeks were more radioresistant with an estimated LD50/30 of 767-787 cGy. Female weanlings were more radiosensitive than males at 3 and 4 weeks old but became significantly more radioresistant after the pubertal age of 5 weeks. The most dramatic increase in body weight, RBC counts and intestinal circumference length occurred from 3 to 5 weeks of age. The established radiomitigator Neulasta® (pegfilgrastim) significantly increased 30-day survival in all age groups, validating these models for MCM efficacy testing. Analyses of DEARE among pediatric survivors revealed depressed weight gain in males six months post-TBI, and increased blood urea nitrogen at 12 months post-TBI which was more severe in females. Hematopoietic DEARE at six months post-TBI appeared to be less severe in survivors from the 3- and 4-week-old groups but was equally severe in all age groups by 12 months of age. Similar to our other acute radiation mouse models, there was no appreciable effect of Neulasta used as an H-ARS MCM on the severity of DEARE. In summary, these data characterize a pediatric mouse model useful for assessing the efficacy of MCMs against ARS and DEARE in children. ©2021 by Radiation Research Society. All rights of reproduction in any form reserved.

Entities:  

Year:  2021        PMID: 33577641     DOI: 10.1667/RADE-20-00259.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  3 in total

1.  Age and Sex Divergence in Hematopoietic Radiosensitivity in Aged Mouse Models of the Hematopoietic Acute Radiation Syndrome.

Authors:  Andrea M Patterson; Sasidhar Vemula; P Artur Plett; Carol H Sampson; Hui Lin Chua; Alexa Fisher; Tong Wu; Rajendran Sellamuthu; Hailin Feng; Barry P Katz; Colleen M DesRosiers; Louis M Pelus; George N Cox; Thomas J MacVittie; Christie M Orschell
Journal:  Radiat Res       Date:  2022-09-01       Impact factor: 3.372

2.  Rat Models of Partial-body Irradiation with Bone Marrow-sparing (Leg-out PBI) Designed for FDA Approval of Countermeasures for Mitigation of Acute and Delayed Injuries by Radiation.

Authors:  Brian L Fish; Thomas J MacVittie; Feng Gao; Jayashree Narayanan; Tracy Gasperetti; Dana Scholler; Yuri Sheinin; Heather A Himburg; Barry Hart; Meetha Medhora
Journal:  Health Phys       Date:  2021-10-01       Impact factor: 2.922

3.  United States medical preparedness for nuclear and radiological emergencies.

Authors:  Andrea L DiCarlo; Mary J Homer; C Norman Coleman
Journal:  J Radiol Prot       Date:  2021-12-06       Impact factor: 1.394

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.